Arcutis Biotherapeutics 

Arcutis Biotherapeutics 

Yahoo Finance • 4 days ago

These healthcare stocks have the highest EPS revision grade ahead of Q3 results

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q3 2026 earnings season approaches, healthcare stocks are drawing investor attention as markets assess earnings e... Full story

Yahoo Finance • last month

The Trade Desk to leave S&P 500 as Bloom Energy, Everpure, Illumina join index

[investor adjusting financial portfolio using digital market data, concept of asset rebalancing, investment strategy, risk management and wealth preservation] primeimages/iStock via Getty Images S&P Dow Jones Indices on Friday said it wil... Full story

Yahoo Finance • last month

Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 21, 2026, to co... Full story

Yahoo Finance • last month

Bloom Energy surges on inclusion to S&P 500; Illumina, Everpure also added

[Stock market data with uptrend vector] sitox Bloom Energy (BE [https://seekingalpha.com/symbol/BE]) jumped 6.2% post-market Friday after the manufacturer of solid oxide fuel cell systems for on-site power generation was added [https://ww... Full story

Yahoo Finance • 2 months ago

Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability

Todd Watanabe, president and CEO of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) sold 4,375 shares on Aug. 3, 2026, according to a recent SEC Form 4 filing. Transaction summary Metric Value Transaction value $114,275 Shares sold 4,375 Pos... Full story

Yahoo Finance • 2 months ago

Arcutis raises 2026 net revenue guidance to $525M-$540M as ZORYVE demand expands and telehealth launches

Earnings Call Insights: Arcutis Biotherapeutics (ARQT) Q2 2026 MANAGEMENT VIEW * "I'm happy to report that once again, we made substantial progress across all 3 pillars during the second quarter" (President, CEO & Director Todd Watanab... Full story

Yahoo Finance • 3 months ago

Arcutis Expands Board of Directors with Appointment of Chris Peetz

Arcutis Biotherapeutics, Inc. Chris PeetzArcutis Expands Board of Directors with Appointment of Chris Peetz WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biop... Full story

Yahoo Finance • 3 months ago

Attovia Therapeutics Appoints John W. Smither to Board of Directors

SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high u... Full story

Yahoo Finance • 3 months ago

Arcutis gets FDA review for Zoryve 0.05% label expansion

[US Food and Drug Administration (FDA)] Arcutis Biotherapeutics (ARQT [https://seekingalpha.com/symbol/ARQT]) announced on Wednesday that the U.S. FDA accepted a supplemental New Drug Application for expanding the label of its Zoryve 0.05... Full story

Yahoo Finance • 3 months ago

Arcutis' ZORYVE Crème SNDA Accepted By FDA For Infants With Atopic Dermatitis

(RTTNews) - Arcutis Biotherapeutics Inc. (ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sND... Full story

Yahoo Finance • 3 months ago

Is Omeros Corporation (OMER) the Best Get Rich Quick Stock to Buy Right Now?

Omeros Corporation (NASDAQ:OMER) is among the best get rich quick stocks to buy right now. On June 26, Brandon Folkes from H.C. Wainwright trimmed the price target on Omeros Corporation (NASDAQ:OMER) to $33 from $40 and reaffirmed a Buy ra... Full story

Yahoo Finance • 3 months ago

Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?

Key Points Arcutis Biotherapeutics is rapidly scaling its Zoryve dermatology line with revenue doubling in its most recent fiscal year. Vertex Pharmaceuticals maintains a dominant position in cystic fibrosis while successfully expanding i... Full story

Yahoo Finance • 4 months ago

Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is among the hidden penny stocks to invest in. As of June 10, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was trading near the low levels reported on June 3, before the stock appreciated followin... Full story

Yahoo Finance • 4 months ago

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.

Pivotal bioVenture Partners Investment Advisor increased its position in Trevi Therapeutics(NASDAQ:TRVI) during the first quarter, acquiring 296,944 shares in an estimated $3.32 million trade based on average quarterly pricing, according t... Full story

Yahoo Finance • 5 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the... Full story

Yahoo Finance • 5 months ago

Arcutis (ARQT) Q1 2026 Earnings Transcript

Image source: The Motley Fool. DATE Wednesday, May 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Todd WatanabeChief Commercial Officer — Todd EdwardsChief Medical Officer — Patrick BurnettChief Finan... Full story

Yahoo Finance • 6 months ago

The Credibility Filter Wall Street Uses to Sort Biotech Winners

VANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid or late stage clinic... Full story

Yahoo Finance • 6 months ago

Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know

Director Howard G. Welgus reported the sale of 10,000 shares of Arcutis Biotherapeutics(NASDAQ:ARQT) on April 1, 2026, according to a SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 10,000 Transaction value $239,... Full story

Yahoo Finance • 7 months ago

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in... Full story

Yahoo Finance • 7 months ago

Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is among the 10 Fastest Growing NASDAQ Stocks to Buy.Guggenheim Raises its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating On February 27, 2026, Guggenheim... Full story